Bibliography
- Chapple C, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26
- Lee K-S, Lee HW, Han DH. Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn Schmiedebergs Arch Pharmacol 2008; DOI: 10.1007/s00210-007-0242-y
- Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841-4
- Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997;81:169-72
- Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 2008;101:1036-42
- Oki T, Maruyama S, Takagi Y, et al. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. Eur J Pharmacol 2006;529:157-63
- Oki T, Kageyama A, Takagi Y, et al. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol 2007;177:766-70
- Mansfield KJ, Vaux K, Millard RJ, et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. Neurourol Urodyn 2005;24:443-4
- Cawello W, Auer S, Hammes W, et al. Multiple dose pharmacokinetics of fesoterodine in human subjects. Naunyn Schmiedebergs Arch Pharmacol 2002;365(Suppl 1):R110
- Nilvebrant L. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol 2002;90:260-7
- Nilvebrant L, Hallen B, Larsson G. Tolterodine – a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997;60:1129-36
- Yono M, Yoshida M, Wada Y, et al. Pharmacological effects of tolterodine on human isolated urinary bladder. Eur J Pharmacol 1999;368:223-30
- Ney P, Stoehr T. M3 selective antimuscarinics affect gastrointestinal transit time in the mouse more potently than nonselective drugs. PDF 2005. Available from: http://www.icsoffice.org/publications/2005/PDF/0558.pdf
- Tsuji A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood–brain barrier. Adv Drug Deliv Rev 1999;36:277-90
- Nilvebrant L, Pahlman I, D'Argy R. Tolterodine and its metabolites show very low penetration into the central nervous system. Int Contin Soc 1999; Abstract 163
- Malhotra B, Wood N, Sachse R, et al. Lipophilicity of 5-hydroxymethyl tolterodine, the active metabolite of fesoterodine. pA2 online 2008; In press
- Cappon GD, Bush B, Newgreen D, et al. Tolterodine does not affect memory assessed by passive-avoidance response test in mice. Eur J Pharmacol 2008;579:225-8
- Suzuki M, Noguchi Y, Okutsu H, et al. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol 2007;557:154-8
- Malone-Lee JG, Walsh JB, Maugourd M-F. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5
- Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002;50:1165-6
- Salvatore S, Serati M, Cardozo L, et al. Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol 2007;197:e8
- Womack KB, Heilman KM. Tolterodine and memory. Dry but forgetful. Arch Neurol 2003;60:771-3
- Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003;349:2274-75
- Diefenbach K, Jaeger K, Wollny A, et al. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. Sleep Med 2008; DOI: 10.1016/j.sleep.2007.07.019
- Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37
- Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998;63:529-39
- Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81:377-85
- Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release formulation. Clin Pharmacokin 2001;40:227-35
- Sachse R, Cawello W, Haag C, et al. Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine. Naunyn Schmiedebergs Arch Pharmacol 2003;367(Suppl 1):R115
- Malhotra B, Wood N, Guan Z, et al. Pharmacokinetic profile of fesoterodine, a novel antimuscarinic treatment for overactive bladder. Br J Clin Pharmacol 2008;65:999-1000
- Bschleipfer T, Schukowski K, Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 2007;80:2303-7
- Zarghooni S, Wunsch J, Bodenbenner M, et al. Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci 2007;80:2308-13
- EMEA: Summary of product characteristics. PDF 2007. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/toviaz/H-723-PI-en.pdf
- Sachse R, Cawello W, Hammes W, et al. Concomitant food intake does not significantly influence the pharmacokinetics of the novel, bladder-selective antimuscarinic fesoterodine. PDF 2004. Available from: http://www.icsoffice.org/publications/2004/PDF/0580.pdf
- Sachse R, Cawello W, Hammes W, et al. Safety and pharmacokinetics of the novel antimuscarinic drug fesoterodine in populations of different age or gender. PDF 2002. Available from: http://www.icsoffice.org/ publications/2002/PDF/441.pdf
- Sachse R, Cawello W, Hammes W, et al. Safety and pharmacokinetics of the novel bladder-selective antimuscarinic fesoterodine in populations of different ethnic origin. PDF 2003. Available from: http://www.icsoffice.org/publications/2003/PDF/377.pdf
- Sachse R, Cawello W, Horstmann R. Safety, tolerability and pharmacokinetics of fesoterodine after co-treatment with the potent cytochrome P450 3A4 inhibitor ketoconazole. PDF 2004. Available from: http://www.icsoffice.org/publications/2004/PDF/0586.pdf
- Sachse R, Krastev Z, Mateva L, et al. Safety, tolerability and pharmacokinetics of fesoterodine in patients with hepatic impairment. PDF 2004. Available from: http://www.icsoffice.org/publications/2004/PDF/0585.pdf
- Malhotra B, Wood N, Guan Z, et al. Fesoterodine pharmacokinetics in subjects with renal impairment versus healthy subjects. Br J Clin Pharmacol 2008;65:998
- Guay DRP. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokin 2003;42:1243-85
- Maniscalco M, Singh-Franco D, Wolowich WR, et al. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther 2006;28:1247-72
- Michel MC, Hegde SS. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists – a matter of metabolites? Naunyn-Schmiedebergs Arch Pharmacol 2006;374:79-85
- Chapple C, Vonkeman H, Hellmis E, et al. Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study. Neurourol Urodyn 2004;23:598-9
- Nitti V, Viatrak M, Kreitman L, et al. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. PDF 2005. Available from: http://www.icsoffice.org/publications/2005/PDF/0306.pdf
- Rovner E, Payne C, Yalla S, et al. Response to fesoterodine in overactive bladder (OAB) patients is independent of the uryodynamic finding of detrusor overactivity. PDF 2005. Available from: http://www.icsoffice.org/publications/2005/PDF/0147.pdf
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
- Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
- Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
- Tubaro A, Wang J, Kopp Z, et al. Improvements in health-related quality of life with fesoterodine in subjets with overactive bladder: pooled data from two randomized controlled studies. PDF 2007. Available from: http://www.icsoffice.org/publications/2007/PDF/0462.pdf
- Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008;71:839-43
- Michel MC, De La Rosette JJ. Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 2005;96(Suppl 1):37-42
- Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomised trials. BJU Int 2008; In press
- Chapple CR, Van Kerrebroeck PE, Jünemann K-P, et al. Comparison of fesoterodine and tolterodine in subjects with overactive bladder. BJU Int 2008; In press
- Olshansky B, Serra DB. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2008;83:231-2
- Dmochowski R, Chen A, Sathyan G, et al. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. J Clin Pharmacol 2005;45:961-8